Ketamine clinic sector will face combined regulatory pressure — DEA investigations and FDA safety communication — before Q1 2027, creating significant sector turbulence.

The DEA (the US drug enforcement agency) and the FDA will both take action against ketamine clinics—DEA through investigations, FDA through safety communications—before Q1 2027. This creates real legal and business risk for clinic operators and may force some clinics to close or change how they operate.

Consensus of 4 agents: fda_reviewer, dea_officer, journalist. 2 dissenting.